<p>Disc Medicine, Inc.（纳斯达克代码：IRON - 获取免费报告）的股票在目前覆盖该公司的十三家券商中被评为 “适度买入”，Marketbeat 报道。一位投资分析师给予该股票卖出评级，十一位分析师给予买入评级，还有一位给予强烈买入评级。在过去一年中更新了对该股票覆盖的分析师的平均一年目标价为 119.00 美元。</p>
<p>获取 <strong>Disc Medicine</strong> 警报：</p>
<p>几位股票研究分析师最近对该公司发表了看法。国家银行股份公司在 10 月 17 日（星期五）的研究报告中将 Disc Medicine 的目标价设定为 153.00 美元。摩根士丹利在 10 月 30 日（星期四）将 Disc Medicine 的目标价从 90.00 美元上调至 115.00 美元，并给予该公司 “超配” 评级。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对 Disc Medicine 股票的 “卖出（d-）” 评级。富国银行在周二将 Disc Medicine 的目标价从 91.00 美元上调至 109.00 美元，并给予该股票 “超配” 评级。最后，Truist Financial 在 11 月 10 日（星期一）将 Disc Medicine 的目标价从 86.00 美元上调至 114.00 美元，并给予该公司 “买入” 评级。</p>
<p><strong>阅读我们对 Disc Medicine 的最新分析</strong></p>
<h2>Disc Medicine 价格表现</h2>
<p>纳斯达克：IRON 在星期五开盘价为 80.04 美元。该公司的 50 日移动平均价为 87.93 美元，200 日移动平均价为 68.73 美元。该公司的市值为 30.2 亿美元，市盈率为-14.96，贝塔值为 0.87。Disc Medicine 的 52 周低点为 30.82 美元，52 周高点为 99.50 美元。该公司的债务与股本比率为 0.05，速动比率为 23.45，流动比率为 23.45。</p>
<p>Disc Medicine（纳斯达克代码：IRON - 获取免费报告）最近在 11 月 6 日（星期四）发布了其财报。该公司报告本季度每股收益为（1.77 美元），低于分析师一致预期的（1.48 美元），差额为（0.29 美元）。作为一个整体，股票研究分析师预计 Disc Medicine 在当前财政年度的每股收益为-4.07 美元。</p>
<h2>内部人士下注</h2>
<p>在其他 Disc Medicine 的新闻中，董事 Kevin Bitterman 在 10 月 8 日（星期三）出售了 71,961 股 Disc Medicine 股票。该股票以平均价格 70.58 美元出售，总价值为 5,079,007.38 美元。交易完成后，该董事在公司持有 500,621 股，价值约为 35,333,830.18 美元。此次交易使其持股减少了 12.57%。该出售在向 SEC 提交的文件中披露，文件可通过此超链接访问。此外，首席执行官 John D. Quisel 在 12 月 11 日（星期四）出售了 40,000 股该股票。该股票以平均价格 93.05 美元出售，总价值为 3,722,000.00 美元。出售后，首席执行官在公司持有 171,828 股，价值为 15,988,595.40 美元。此次交易使其持股减少了 18.88%。该出售的披露信息可在 SEC 文件中找到。内部人士在上个季度出售了 451,555 股公司股票，价值为 38,742,458 美元。3.64% 的股票由内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近对该公司的持仓进行了调整。Hudson Bay Capital Management LP 在第三季度购买了 Disc Medicine 的新股份，价值约为 6,752,000 美元。Verition Fund Management LLC 在第三季度获得了 Disc Medicine 的新持仓，价值约为 405,000 美元。Vestal Point Capital LP 在第三季度将其在 Disc Medicine 的持仓增加了 257.1%。Vestal Point Capital LP 现在持有 500,000 股该公司的股票，价值为 33,040,000 美元，此前在上个季度又购买了 360,000 股。Palo Alto Investors LP 在第三季度将其在 Disc Medicine 的持仓增加了 54.0%。Palo Alto Investors LP 现在持有 224,300 股该公司的股票，价值为 14,822,000 美元，此前在上个季度又购买了 78,609 股。最后，Millennium Management LLC 在第三季度将其在 Disc Medicine 的持仓增加了 340.0%。Millennium Management LLC 现在持有 161,000 股该公司的股票，价值为 10,639,000 美元，此前在上个季度又购买了 124,407 股。83.70% 的股票由机构投资者持有。</p>
<h2>关于 Disc Medicine</h2>
<p>（获取免费报告）</p>
<p>Disc Medicine, Inc.（纳斯达克：IRON）是一家临床阶段的生物技术公司，专注于发现和开发恢复严重遗传和获得性疾病正常细胞功能的精准药物。该公司采用以化学为驱动的方法，识别选择性调节 RNA 结合蛋白或剪接调控通路的小分子。通过利用专有的筛选和药物化学平台，Disc Medicine 旨在解决具有高度未满足医疗需求和有限治疗选择的疾病。</p>
<p>该公司的产品管线以针对神经肌肉和血液疾病的主要项目为基础。</p>
<h2>精选文章</h2>
<ul>
<li>我们更喜欢的五只股票超过 Disc Medicine</li>
<li>如何投资生物技术股票</li>
<li>耐克在收益上超出预期，但在中国面临困难并遭遇关税</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>人工智能热潮是泡沫吗？这两只分红股票说不是</li>
<li>价值投资：在 2022 年这是一个好策略吗？提示：永远</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJPTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJPTg"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Disc Medicine 吗？</h2>
<p>在考虑 Disc Medicine 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Disc Medicine 并不在名单上。</p>
<p>虽然 Disc Medicine 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IRON

<p>Disc Medicine, Inc.（纳斯达克代码：IRON）获得了 13 家券商的 “适度买入” 共识评级。分析师设定的平均 1 年目标价为 119.00 美元。最近的价格目标包括国家银行股份公司设定的 153.00 美元和摩根士丹利设定的 115.00 美元。该股票开盘价为 80.04 美元，52 周范围为 30.82 美元至 99.50 美元。内部人士在上个季度出售了价值 3870 万美元的股票，机构投资者持有该股票的 83.70%</p>

<p>Shares of Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) have been assigned an average rating of &#34;Moderate Buy&#34; from the thirteen brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $119.00.</p>
<div class="lb-trans"><p>Disc Medicine, Inc.（纳斯达克代码：IRON - 获取免费报告）的股票在目前覆盖该公司的十三家券商中被评为 “适度买入”，Marketbeat 报道。一位投资分析师给予该股票卖出评级，十一位分析师给予买入评级，还有一位给予强烈买入评级。在过去一年中更新了对该股票覆盖的分析师的平均一年目标价为 119.00 美元。</p>
</div><p>Get <strong>Disc Medicine</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Disc Medicine</strong> 警报：</p>
</div><p>Several equities research analysts have recently weighed in on the company. National Bankshares set a $153.00 price objective on Disc Medicine in a research note on Friday, October 17th. Morgan Stanley lifted their price objective on Disc Medicine from $90.00 to $115.00 and gave the company an &#34;overweight&#34; rating in a report on Thursday, October 30th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Disc Medicine in a research note on Wednesday, October 8th. Wells Fargo &amp; Company increased their target price on shares of Disc Medicine from $91.00 to $109.00 and gave the stock an &#34;overweight&#34; rating in a research report on Tuesday. Finally, Truist Financial lifted their price target on shares of Disc Medicine from $86.00 to $114.00 and gave the company a &#34;buy&#34; rating in a report on Monday, November 10th.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该公司发表了看法。国家银行股份公司在 10 月 17 日（星期五）的研究报告中将 Disc Medicine 的目标价设定为 153.00 美元。摩根士丹利在 10 月 30 日（星期四）将 Disc Medicine 的目标价从 90.00 美元上调至 115.00 美元，并给予该公司 “超配” 评级。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对 Disc Medicine 股票的 “卖出（d-）” 评级。富国银行在周二将 Disc Medicine 的目标价从 91.00 美元上调至 109.00 美元，并给予该股票 “超配” 评级。最后，Truist Financial 在 11 月 10 日（星期一）将 Disc Medicine 的目标价从 86.00 美元上调至 114.00 美元，并给予该公司 “买入” 评级。</p>
</div><p><strong>Read Our Latest Analysis on Disc Medicine</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Disc Medicine 的最新分析</strong></p>
</div><h2>Disc Medicine Price Performance</h2>
<div class="lb-trans"><h2>Disc Medicine 价格表现</h2>
</div><p>NASDAQ:IRON opened at $80.04 on Friday. The company has a 50-day moving average of $87.93 and a 200-day moving average of $68.73. The company has a market capitalization of $3.02 billion, a price-to-earnings ratio of -14.96 and a beta of 0.87. Disc Medicine has a 52 week low of $30.82 and a 52 week high of $99.50. The company has a debt-to-equity ratio of 0.05, a quick ratio of 23.45 and a current ratio of 23.45.</p>
<div class="lb-trans"><p>纳斯达克：IRON 在星期五开盘价为 80.04 美元。该公司的 50 日移动平均价为 87.93 美元，200 日移动平均价为 68.73 美元。该公司的市值为 30.2 亿美元，市盈率为-14.96，贝塔值为 0.87。Disc Medicine 的 52 周低点为 30.82 美元，52 周高点为 99.50 美元。该公司的债务与股本比率为 0.05，速动比率为 23.45，流动比率为 23.45。</p>
</div><p>Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share for the quarter, missing analysts' consensus estimates of ($1.48) by ($0.29). As a group, equities research analysts anticipate that Disc Medicine will post -4.07 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Disc Medicine（纳斯达克代码：IRON - 获取免费报告）最近在 11 月 6 日（星期四）发布了其财报。该公司报告本季度每股收益为（1.77 美元），低于分析师一致预期的（1.48 美元），差额为（0.29 美元）。作为一个整体，股票研究分析师预计 Disc Medicine 在当前财政年度的每股收益为-4.07 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Disc Medicine news, Director Kevin Bitterman sold 71,961 shares of Disc Medicine stock in a transaction on Wednesday, October 8th. The stock was sold at an average price of $70.58, for a total value of $5,079,007.38. Following the completion of the transaction, the director owned 500,621 shares in the company, valued at approximately $35,333,830.18. The trade was a 12.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO John D. Quisel sold 40,000 shares of the stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $93.05, for a total value of $3,722,000.00. Following the sale, the chief executive officer owned 171,828 shares in the company, valued at $15,988,595.40. The trade was a 18.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 451,555 shares of company stock valued at $38,742,458 over the last quarter. 3.64% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他 Disc Medicine 的新闻中，董事 Kevin Bitterman 在 10 月 8 日（星期三）出售了 71,961 股 Disc Medicine 股票。该股票以平均价格 70.58 美元出售，总价值为 5,079,007.38 美元。交易完成后，该董事在公司持有 500,621 股，价值约为 35,333,830.18 美元。此次交易使其持股减少了 12.57%。该出售在向 SEC 提交的文件中披露，文件可通过此超链接访问。此外，首席执行官 John D. Quisel 在 12 月 11 日（星期四）出售了 40,000 股该股票。该股票以平均价格 93.05 美元出售，总价值为 3,722,000.00 美元。出售后，首席执行官在公司持有 171,828 股，价值为 15,988,595.40 美元。此次交易使其持股减少了 18.88%。该出售的披露信息可在 SEC 文件中找到。内部人士在上个季度出售了 451,555 股公司股票，价值为 38,742,458 美元。3.64% 的股票由内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently made changes to their positions in the business. Hudson Bay Capital Management LP bought a new stake in Disc Medicine during the 3rd quarter worth about $6,752,000. Verition Fund Management LLC acquired a new position in shares of Disc Medicine during the third quarter worth approximately $405,000. Vestal Point Capital LP grew its stake in shares of Disc Medicine by 257.1% during the third quarter. Vestal Point Capital LP now owns 500,000 shares of the company's stock valued at $33,040,000 after purchasing an additional 360,000 shares during the last quarter. Palo Alto Investors LP increased its holdings in shares of Disc Medicine by 54.0% in the third quarter. Palo Alto Investors LP now owns 224,300 shares of the company's stock valued at $14,822,000 after purchasing an additional 78,609 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in Disc Medicine by 340.0% during the 3rd quarter. Millennium Management LLC now owns 161,000 shares of the company's stock worth $10,639,000 after buying an additional 124,407 shares in the last quarter. 83.70% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>机构投资者最近对该公司的持仓进行了调整。Hudson Bay Capital Management LP 在第三季度购买了 Disc Medicine 的新股份，价值约为 6,752,000 美元。Verition Fund Management LLC 在第三季度获得了 Disc Medicine 的新持仓，价值约为 405,000 美元。Vestal Point Capital LP 在第三季度将其在 Disc Medicine 的持仓增加了 257.1%。Vestal Point Capital LP 现在持有 500,000 股该公司的股票，价值为 33,040,000 美元，此前在上个季度又购买了 360,000 股。Palo Alto Investors LP 在第三季度将其在 Disc Medicine 的持仓增加了 54.0%。Palo Alto Investors LP 现在持有 224,300 股该公司的股票，价值为 14,822,000 美元，此前在上个季度又购买了 78,609 股。最后，Millennium Management LLC 在第三季度将其在 Disc Medicine 的持仓增加了 340.0%。Millennium Management LLC 现在持有 161,000 股该公司的股票，价值为 10,639,000 美元，此前在上个季度又购买了 124,407 股。83.70% 的股票由机构投资者持有。</p>
</div><h2>About Disc Medicine</h2>
<div class="lb-trans"><h2>关于 Disc Medicine</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.</p>
<div class="lb-trans"><p>Disc Medicine, Inc.（纳斯达克：IRON）是一家临床阶段的生物技术公司，专注于发现和开发恢复严重遗传和获得性疾病正常细胞功能的精准药物。该公司采用以化学为驱动的方法，识别选择性调节 RNA 结合蛋白或剪接调控通路的小分子。通过利用专有的筛选和药物化学平台，Disc Medicine 旨在解决具有高度未满足医疗需求和有限治疗选择的疾病。</p>
</div><p>The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.</p>
<div class="lb-trans"><p>该公司的产品管线以针对神经肌肉和血液疾病的主要项目为基础。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Disc Medicine</li>
<li>How to Invest in Biotech Stocks</li>
<li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li>
<li>Stock Splits, Do They Really Impact Investors?</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
<li>Value Investing: Is it a Good Strategy in 2022? Hint: Always</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票超过 Disc Medicine</li>
<li>如何投资生物技术股票</li>
<li>耐克在收益上超出预期，但在中国面临困难并遭遇关税</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>人工智能热潮是泡沫吗？这两只分红股票说不是</li>
<li>价值投资：在 2022 年这是一个好策略吗？提示：永远</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJPTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=IRON"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Disc Medicine Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Disc Medicine 吗？</h2>
</div><p>Before you consider Disc Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Disc Medicine 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Disc Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Disc Medicine 并不在名单上。</p>
</div><p>While Disc Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Disc Medicine 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Disc Medicine, Inc.（NASDAQ: IRON）被券商一致评为 “适度买入”